Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Saad, Mohamed O

Saad, Mohamed O.

Saad MO; Department of Pharmacy, Al-Wakra Hospital, Hamad Medical Corporation, PO Box 82228 Doha, Qatar. Electronic address: msaad4@hamad.qa.

Int J Antimicrob Agents ; 57(1): 106171, 2021 Jan.

Article in English | MEDLINE | ID: covidwho-1065123

Subject(s)

Antiviral Agents/therapeutic use; Azithromycin/therapeutic use; COVID-19 Drug Treatment; Hydroxychloroquine/therapeutic use; SARS-CoV-2/pathogenicity; Anti-Bacterial Agents/therapeutic use; Antimalarials/therapeutic use; COVID-19/virology; Clinical Trials as Topic; Drug Combinations; Drug Repositioning; Humans; Uncertainty

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Azithromycin / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google